Search

Your search keyword '"De Meulder, B"' showing total 7 results
Start Over Author "De Meulder, B" Journal european urology open science
7 results on '"De Meulder, B"'

1. Analysis of clinical characteristics in metastatic hormone-sensitive prostate cancer: Bridging the gap between randomized controlled trials and real-world data

Author

Gómez Rivas, J., primary, Nicoletti, R., additional, Ibanez, L., additional, Golozar, A., additional, Steinbeißer, C., additional, De Meulder, B., additional, Snijder, R., additional, Axelsson, S.E., additional, Ayman, H., additional, Feng, Q., additional, Bjartell, A., additional, Cornford, P., additional, Murtola, T., additional, Willemse, P.P., additional, Prinsen, P., additional, and N dow, J., additional

Published
2023
Full Text
View/download PDF

2. Real-world data analysis of treatment outcomes for patients with metastatic hormone-sensitive prostate cancer: development of a survival prediction model. Results from the European network of excellence for big data in prostate cancer (PIONEER)

Author

Gómez Rivas, J., primary, Nicoletti, R., additional, Golozar, A., additional, Ayman, H., additional, Steinbeißer, C., additional, Ibañez, L., additional, De Meulder, B., additional, Axelsson, S.E., additional, Snijder, R., additional, Feng, Q., additional, Bjartell, A., additional, Cornford, P., additional, Willemse, P., additional, Prinsen, P., additional, Murtola, T.J., additional, and N´dow, J., additional

Published
2023
Full Text
View/download PDF

3. Real-world data analysis of clinical characteristics in metastatic hormone-sensitive prostate cancer: Are patients from RCTs the same from real life? Data from the European network of excellence for big data in prostate cancer (PIONEER).

Author

Gómez Rivas, J., primary, Nicoletti, R., additional, Golozar, A., additional, Steinbeißer, C., additional, De Meulder, B., additional, Snijder, R., additional, Ibañez, L., additional, Axelsson, S.E., additional, Ayman, H., additional, Feng, Q., additional, Murtola, T.J., additional, Bjartell, A., additional, Cornford, P., additional, Willemse, P., additional, Prinsen, P., additional, and N´dow, J., additional

Published
2023
Full Text
View/download PDF

4. P129 - Real-world data analysis of treatment outcomes for patients with metastatic hormone-sensitive prostate cancer: development of a survival prediction model. Results from the European network of excellence for big data in prostate cancer (PIONEER)

Author

Gómez Rivas, J., Nicoletti, R., Golozar, A., Ayman, H., Steinbeißer, C., Ibañez, L., De Meulder, B., Axelsson, S.E., Snijder, R., Feng, Q., Bjartell, A., Cornford, P., Willemse, P., Prinsen, P., Murtola, T.J., and N´dow, J.

Published
2023
Full Text
View/download PDF

5. P096 - Real-world data analysis of clinical characteristics in metastatic hormone-sensitive prostate cancer: Are patients from RCTs the same from real life? Data from the European network of excellence for big data in prostate cancer (PIONEER).

Author

Gómez Rivas, J., Nicoletti, R., Golozar, A., Steinbeißer, C., De Meulder, B., Snijder, R., Ibañez, L., Axelsson, S.E., Ayman, H., Feng, Q., Murtola, T.J., Bjartell, A., Cornford, P., Willemse, P., Prinsen, P., and N´dow, J.

Published
2023
Full Text
View/download PDF

6. PIONEER: European Commission Innovative Medicines Initiative funded BD4BO (Big data for better outcome) project on prostate cancer

Author

Evans Axelsson, S., primary, Abbott, T., additional, Fullwood, L., additional, Omar, M.I., additional, Cavelaars, M., additional, Asiimwe, A., additional, Roobol, M., additional, Ribal, M.J., additional, Auffray, C., additional, Devecseri, Z., additional, Smith, E.J., additional, Van Hemelrijck, M., additional, MacLennan, S., additional, Horgan, D., additional, Reich, C., additional, De Meulder, B., additional, Lancet, D., additional, Bangma, C., additional, Briganti, A., additional, Tilki, D., additional, Van Poppel, H., additional, Wirth, M.P., additional, N’Dow, J., additional, and Bjartell, A., additional

Published
2020
Full Text
View/download PDF

7. Research Protocol for an Observational Health Data Analysis on the Adverse Events of Systemic Treatment in Patients with Metastatic Hormone-sensitive Prostate Cancer: Big Data Analytics Using the PIONEER Platform.

Author

Rajwa P, Borkowetz A, Abbott T, Alberti A, Bjartell A, Brash JT, Campi R, Chilelli A, Conover M, Constantinovici N, Davies E, De Meulder B, Eid S, Gacci M, Golozar A, Hafeez H, Haque S, Hijazy A, Hulsen T, Josefsson A, Khalid S, Kolde R, Kotik D, Kurki S, Lambrecht M, Leung CH, Moreno J, Nicoletti R, Nieboer D, Oja M, Palanisamy S, Prinsen P, Reich C, Raffaele Resta G, Ribal MJ, Gómez Rivas J, Smith E, Snijder R, Steinbeisser C, Vandenberghe F, Cornford P, Evans-Axelsson S, N'Dow J, and Willemse PM

Abstract

Combination therapies in metastatic hormone-sensitive prostate cancer (mHSPC), which include the addition of an androgen receptor signaling inhibitor and/or docetaxel to androgen deprivation therapy, have been a game changer in the management of this disease stage. However, these therapies come with their fair share of toxicities and side effects. The goal of this observational study is to report drug-related adverse events (AEs), which are correlated with systemic combination therapies for mHSPC. Determining the optimal treatment option requires large cohorts to estimate the tolerability and AEs of these combination therapies in "real-life" patients with mHSPC, as provided in this study. We use a network of databases that includes population-based registries, electronic health records, and insurance claims, containing the overall target population and subgroups of patients defined by unique certain characteristics, demographics, and comorbidities, to compute the incidence of common AEs associated with systemic therapies in the setting of mHSPC. These data sources are standardised using the Observational Medical Outcomes Partnership Common Data Model. We perform the descriptive statistics as well as calculate the AE incidence rate separately for each treatment group, stratified by age groups and index year. The time until the first event is estimated using the Kaplan-Meier method within each age group. In the case of episodic events, the anticipated mean cumulative counts of events are calculated. Our study will allow clinicians to tailor optimal therapies for mHSPC patients, and they will serve as a basis for comparative method studies., (© 2024 The Authors.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results